Psychosocial function after hematopoietic stem cell transplantation

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a critical treatment for chronic myelogenous leukemia (CML).
• Patient-reported outcomes like quality of life (QOL) and mood are crucial in assessing treatment success.
• Alcohol consumption is a modifiable behavior with potential impacts on health outcomes post-transplantation.

Purpose of the Study:

• To prospectively evaluate the longitudinal changes in quality of life and mood in CML patients undergoing allogeneic HSCT.
• To assess patterns of alcohol consumption and their progression during the follow-up period after HSCT.
• To identify factors influencing QOL, mood, and alcohol use post-transplantation.

Main Methods:

• Prospective cohort study design.
• Serial assessments of QOL, mood (depressive symptoms), and alcohol consumption at admission, 6 months, and 12 months post-HSCT.
• Inclusion of 84 patients who completed initial assessments and follow-up.

Main Results:

• Significant improvements in overall quality of life were observed over 12 months.
• A decline in measures of depressive symptoms was noted during the follow-up period.
• Patients demonstrated a reduction in overall alcohol consumption by the 12-month follow-up.

Conclusions:

• Time is a significant factor in the positive recovery trajectory of CML patients post-HSCT.
• Allogeneic HSCT may lead to improved psychological well-being and healthier lifestyle choices, including reduced alcohol intake.
• Longitudinal monitoring of QOL, mood, and behavior is essential for comprehensive patient care after transplantation.